Publications by authors named "Kaitlin Yablonski"
Background: Dual programmed cell death protein (ligand)-1 (PD-[L]1) and lymphocyte-activation gene-3 (LAG-3) blockade has demonstrated improved anti-tumour response in some advanced solid tumours. CITRINO, a two-part, Phase 1 dose-escalation study, evaluated encelimab (TSR-033; novel anti-LAG-3) monotherapy and in combination in patients with advanced/metastatic solid tumours.
Methods: Part 1 (P1) involved dose escalation (20-720 mg Q2W) of encelimab as monotherapy (P1A/B) and with dostarlimab (500 mg Q3W) in patients with previously treated advanced/metastatic solid tumours (P1C).
Article Synopsis
- The ENGAGE-1 study tested the monoclonal antibody GSK3174998 alone or with pembrolizumab in patients with advanced solid tumors to evaluate safety, tolerability, and clinical activity.
- Adverse events were reported in 51% of patients receiving GSK3174998 alone and 64% in those receiving it with pembrolizumab, with fatigue being the most common.
- Limited clinical activity was observed, and specific immune cell changes in the tumor microenvironment may explain some treatment responses; however, the overall efficacy did not exceed expectations based on pembrolizumab alone.